Inexpensive iron salts are a key to simplifying the manufacture of essential precursors for drugs and other chemicals, according to scientists at Rice University.
The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.
Research at Roswell Park Comprehensive Cancer Center shows that putting a three-day limit on opioid prescriptions to treat surgical pain after hospital discharge reduces the number of patients who become chronic opioid users without compromising pain relief or recovery. It also reduces the amount of opioids circulating in the community — a grave concern, given that opioids are implicated in 130 overdose deaths in the U.S. every day.
A chemistry collaboration led to a creative way to put carbon dioxide to good – and even healthy – use: by incorporating it, via electrosynthesis, into a series of organic molecules that are vital to pharmaceutical development.
Scientists from St. Jude Children’s Research Hospital performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response.
Wayne State's Dr. Jamesdaniel received a $1.7 million NIH grant to study cisplatin, a drug that is prescribed to 10 to 20% of cancer patients that causes hearing loss in up to 80% treated with the drug.
Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.
Research has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug. The study, published in the Proceedings of the National Academy of Sciences, has the potential to transform treatment for this rare disease and may also have implications for more common diseases.
Following a modified Atkins diet high in fat and low in carbohydrates plus taking medication may reduce seizures in people with tough-to-treat epilepsy, according to a study published in the January 4, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A team from 15 U.S. medical centers led by UT Southwestern Simmons Cancer Center researchers has performed the first analysis of a potentially game-changing drug to treat upper urinary tract urothelial cancers.
SLAS, the Society of Laboratory Automation and Screening, announces the addition of three new board members who will carry out three-year terms beginning January 1, 2023.
Insulin is an essential hormone for humans and many other living creatures. Its best-known task is to regulate sugar metabolism. How it does this job is well understood.
Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement with AJU Pharm Co. Ltd. (hereinafter AJU), for Stuart's clinical stage drug candidate ST-100.
All patients undergoing procedures requiring anesthesia should be asked about cannabis use, according to guidelines released by the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine). The first U.S. guidelines on cannabis use in relation to surgery also notes regular use may worsen pain and nausea after surgery and increase the need for opioids.
Not for public release
This news release is embargoed until 2-Jan-2023 5:00 PM EST
Released to reporters: 27-Dec-2022 2:00 PM EST
A reporter's PressPass is required to
access this story until the embargo expires on 2-Jan-2023 5:00 PM EST
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), was awarded the C. E. Alken Prize in recognition of his outstanding scientific uro-oncological work.
An international team of researchers including Sofya Kulikova, Senior Research Fellow at the HSE University-Perm, found that ketamine, being an NMDA receptor inhibitor, increases the brain's background noise, causing higher entropy of incoming sensory signals and disrupting their transmission between the thalamus and the cortex.
Clinical scientists with UC Davis and University of Cincinnati perform first-of-its-kind analysis showing a clear difference in cost-effectiveness of medication types for life-threatening condition
Columbia Engineering researchers report that they have developed a new experimental pipeline to combine bacterial therapy with current cancer drugs. Their study, which explores resistance to bacterial therapy at the molecular level, has achieved better treatment efficacy without additional toxicity in laboratory models.
Pathogens such as SARS-CoV-2 and pneumococcus can cause severe pneumonia. If the airways then fill with fluid, the patient risks developing acute respiratory distress syndrome.
Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States. Patients with the condition typically have inflammation throughout their esophagus and trouble swallowing food – known as dysphagia.Without proper treatment, the lining of the esophagus becomes fibrous, and the passage becomes so narrowed, or strictured, that food can lodge in the esophagus, requiring medical attention.
In a study published December 8, 2022 in Science, UCSF researchers Kevin Lou, an MD-PhD student, Luke Gilbert, PhD, and Kevan Shokat, PhD, reveal the discovery of a cellular uptake pathway important for larger molecules. These large and complex molecules bind in unconventional ways to their targets, are efficiently taken up by target cells, and can be harnessed to create new drugs for the treatment of cancer and other diseases.
Tonia Vincent, Professor of Musculoskeletal Biology & Honorary Rheumatologist at Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), said: ‘Hand osteoarthritis is a common and debilitating medical condition that affects mainly women, especially around the time of the menopause.
An international research group including scientists from Italy, the United States, Ireland, and Israel have published a three-year analysis of the Mesothelioma (Me) drug trial, Check-Mate 743 (CM-743).
Researchers have designed and synthesized analogs of a new antibiotic that is effective against multidrug-resistant bacteria, opening a new front in the fight against these infections.
Wastewater sampling has shown the significant impact of removing the strong painkiller codeine from pharmacy counters to a prescription-only medication since 2018 in Australia. The move has led to a 37 per cent drop in codeine use, cutting dependency and potentially saving lives.
A Sudan ebolavirus vaccine and antibody therapeutic tested at Texas Biomedical Research Institute have been sent to Uganda as part of efforts to control the outbreak there.
Researchers from Boston Children’s Hospital and Harvard, using Argonne’s Advanced Photon Source, have characterized the structure of integrins, a type of cell surface receptor involved in the immune response.
A new combination of drugs slowed the growth of cancer cells by an unexpected mechanism that may one day lead to improved treatment of cervical cancer, a UT Southwestern-led study published in Molecular Cancer Research suggests.
Scientists at Baltic Federal University have suggested evaluating concentration and chemical composition of drugs by means of vibrational spectroscopy and nuclear magnetic resonance instead of conventional complex approaches
The U.S. Food and Drug Administration has approved the targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Thoracic surgeons at the Center for Precision Surgery in the Abramson Cancer Center at Penn Medicine led the clinical trials evaluating the imaging agent in lung cancer, in a partnership with On Target Laboratories.
Metformin, the most prescribed drug for treating diabetes mellitus, known as type 2 diabetes, requires the presence of the growth differentiation factor 15 (GDF15) —a protein whose expression increases in response to cellular stress— to present its antidiabetic effects.
With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment.
The latest guidance in addressing proper monitoring and reversal of neuromuscular blockade drugs during general anesthesia – a major advance in patient safety and satisfaction – was published today in Anesthesiology, the American Society of Anesthesiologist’s (ASA) peer-reviewed medical journal.
Abhinav Jha, at the McKelvey School of Engineering, wants to use novel imaging to better understand how people absorb radiation therapy. His team won a four-year $2.2 million National Institutes of Health (NIH) grant for the study, which aims to guide treatment decisions.
As human lifespans increase, so does general memory impairment – calling for the need to expand research for dementia treatment. The key to this expansion is the center focus of the SLAS Discovery featured article, “A neuronal cell-based reporter system for monitoring the activity of HDAC2” by Unemura, et al.
An analysis of combined pharmacotherapy for reducing drinking and smoking validated findings that measuring reductions in the amount of drinking, not just abstinence, was an effective outcome for alcohol medication trials.
Pesquisadores da Mayo Clinic dizem que o anticorpo monoclonal bebtelovimabe (já autorizado pela Food and Drug Administration para uso emergencial na variante ômicron da COVID-19) é uma opção confiável para tratar a BA.2 e outras subvariantes da COVID-19. As descobertas do estudo retrospectivo realizado vários locais, envolvendo 3.607 pacientes de alto risco foram publicadas na revista médica Journal of Infectious Diseases.
Los investigadores de Mayo Clinic informan que el anticuerpo monoclonal bebtelovimab, ya autorizado por la Administración de Alimentos y Medicamentos de Estados Unidos para usar en emergencias de la variante ómicron de la COVID-19, es una alternativa confiable para tratar a la BA.2 y otras subvariantes de la COVID-19. Los resultados del estudio retrospectivo que se realizó en varios sitios con 3607 pacientes de alto riesgo se publicaron en Journal of Infectious Diseases (Revista de Enfermedades Infecciosas).
مدينة روتشستر، ولاية مينيسوتا - يقول باحثو مايو كلينك إن الجسم المضاد أحادي النسيلة ببتيلوفيماب، المُرخص بالفعل من قبل إدارة الغذاء والدواء الأمريكية للاستخدام في حالات الطوارئ الخاصة بمتحور أوميكرون من فيروس كورونا المستجد (كوفيد-19)، هو خيار موثوق لعلاج سلالة BA.2 والمتحورات الفرعية الأخرى لفيروس كورونا المستجد (كوفيد-19). ونتائج دراستهم الاسترجاعية متعددة المواقع والتي شملت 3,607 مريضًا معرضين لمخاطر عالية، منشورة في مجلة الأمراض المعدية.
A retrospective cohort study of more than 44,000 nonhospitalized persons diagnosed with COVID-19 found that nirmatrelvir plus ritonavir reduced the overall risk of hospitalization and death. The study is published in Annals of Internal Medicine.
Researchers from Tel Aviv University developed a new technology that will allow controlled encapsulation and release of molecules by exposure to UV light.
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania’s Abramson Cancer Center at the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract 565).
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped